Ann: First quarter sales update, page-24

Just reading the budget announcements and considering the various companies I’m invested in. Of them GSS is in a prime position to benefit - R&D rebates preserved, no cap on instant asset write off - as they invest in machine and equipment to scale up - if they are profitable this year and it looks to be in the order of $20m profit the tax can be cash backed to fund expansion on FY 22 - if GSS didn’t have a suite of game changing products lined up - this wouldn’t be such a boost but it will really make every dollar generated able to be reinvested - as we try to break into Europe this is such a support for Aussie innovation. This super cycle is going to play out over the next few years. I can imagine pathology companies will be investing big time in machines. Thought tests - would sell everything they could make for the next few years... I didn’t think the machines would too. Very exciting times to be an investor backing innovation and start ups